Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.
La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia.
ACS Chem Biol. 2020 Apr 17;15(4):962-969. doi: 10.1021/acschembio.9b00996. Epub 2020 Mar 30.
Cyclotides are a class of cyclic disulfide-rich peptides found in plants that have been adopted as a molecular scaffold for pharmaceutical applications due to their inherent stability and ability to penetrate cell membranes. For research purposes, they are usually produced and cyclized synthetically, but there are concerns around the cost and environmental impact of large-scale chemical synthesis. One strategy to improve this is to combine a recombinant production system with native enzyme-mediated cyclization. Asparaginyl endopeptidases (AEPs) are enzymes that can act as peptide ligases in certain plants to facilitate cyclotide maturation. One of these ligases, OaAEP1b, originates from the cyclotide-producing plant, , and can be produced recombinantly for use as an alternative to chemical cyclization of recombinant substrates. However, not all engineered cyclotides are compatible with AEP-mediated cyclization because new pharmaceutical epitopes often replace the most flexible region of the peptide, where the native cyclization site is located. Here we redesign a popular cyclotide grafting scaffold, MCoTI-II, to incorporate an AEP cyclization site located away from the usual grafting region. We demonstrate the incorporation of a bioactive peptide sequence in the most flexible region of MCoTI-II while maintaining AEP compatibility, where the two were previously mutually exclusive. We anticipate that our AEP-compatible scaffold, based on the most popular cyclotide for pharmaceutical applications, will be useful in designing bioactive cyclotides that are compatible with AEP-mediated cyclization and will therefore open up the possibility of larger scale enzyme-mediated production of recombinant or synthetic cyclotides alike.
环肽是一类存在于植物中的富含二硫键的肽,由于其固有稳定性和穿透细胞膜的能力,已被用作药物应用的分子支架。出于研究目的,它们通常通过合成方式进行生产和环化,但大规模化学合成的成本和环境影响引起了人们的关注。一种改进方法是将重组生产系统与天然酶介导的环化相结合。天冬酰胺内肽酶(AEPs)是一类能够在某些植物中充当肽连接酶的酶,有助于环肽成熟。其中一种连接酶 OaAEP1b 来自于产环肽植物 ,可以通过重组生产用于替代重组底物的化学环化。然而,并非所有工程化的环肽都与 AEP 介导的环化兼容,因为新的药物表位经常取代肽中最灵活的区域,而天然环化位点位于该区域。在这里,我们重新设计了一种流行的环肽嫁接支架 MCoTI-II,以纳入远离通常嫁接区域的 AEP 环化位点。我们证明了在 MCoTI-II 的最灵活区域中掺入生物活性肽序列,同时保持 AEP 兼容性,而这两个以前是相互排斥的。我们预计,我们基于最受欢迎的用于药物应用的环肽的 AEP 兼容支架将有助于设计与 AEP 介导的环化兼容的生物活性环肽,从而为更大规模的酶介导生产重组或合成环肽提供可能性。